Key Points
- Insider sale: Adaptive Biotechnologies insider Susan Bobulsky sold 5,000 shares on June 11 at an average price of $19.00, totaling $95,000. The sale was made under a pre-arranged Rule 10b5-1 trading plan, and she still holds 411,775 shares.
- Recent company performance: The company beat earnings expectations in its latest quarter, posting EPS of -$0.13 versus the expected -$0.16 and revenue of $70.87 million versus $61.03 million estimated. Revenue rose 35.1% year over year.
- Wall Street view: Analysts remain broadly constructive on ADPT, with six Buy ratings, one Hold, and one Sell. The consensus rating is Moderate Buy with a price target of $19.57.
Adaptive Biotechnologies Corporation (NASDAQ:ADPT - Get Free Report) insider Susan Bobulsky sold 5,000 shares of the stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $19.00, for a total transaction of $95,000.00. Following the completion of the transaction, the insider directly owned 411,775 shares of the company's stock, valued at $7,823,725. This trade represents a 1.20% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Susan Bobulsky also recently made the following trade(s):
- On Thursday, June 4th, Susan Bobulsky sold 11,000 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $18.00, for a total value of $198,000.00.
Adaptive Biotechnologies Trading Down 0.8%
Shares of ADPT opened at $17.46 on Tuesday. The stock has a market cap of $2.79 billion, a PE ratio of -52.91 and a beta of 2.16. Adaptive Biotechnologies Corporation has a 1 year low of $9.96 and a 1 year high of $20.76. The stock has a 50 day simple moving average of $14.62 and a 200-day simple moving average of $15.63.
Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) last announced its quarterly earnings results on Tuesday, May 5th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.16) by $0.03. Adaptive Biotechnologies had a negative return on equity of 40.06% and a negative net margin of 16.82%.The business had revenue of $70.87 million for the quarter, compared to analyst estimates of $61.03 million. During the same quarter in the previous year, the firm earned ($0.20) EPS. Adaptive Biotechnologies's quarterly revenue was up 35.1% on a year-over-year basis. On average, sell-side analysts forecast that Adaptive Biotechnologies Corporation will post -0.47 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of equities research analysts recently weighed in on the company. TD Cowen raised their price target on Adaptive Biotechnologies from $19.00 to $21.00 and gave the company a "buy" rating in a report on Wednesday, May 6th. Morgan Stanley reduced their price objective on Adaptive Biotechnologies from $21.00 to $18.00 and set an "equal weight" rating on the stock in a research note on Tuesday, May 12th. JPMorgan Chase & Co. decreased their target price on Adaptive Biotechnologies from $21.00 to $19.00 and set an "overweight" rating on the stock in a report on Wednesday, May 6th. BTIG Research restated a "buy" rating and issued a $22.00 target price on shares of Adaptive Biotechnologies in a research note on Wednesday, May 6th. Finally, Wall Street Zen cut Adaptive Biotechnologies from a "buy" rating to a "hold" rating in a report on Saturday, March 7th. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $19.57.
Read Our Latest Stock Analysis on ADPT
Institutional Trading of Adaptive Biotechnologies
Hedge funds and other institutional investors have recently modified their holdings of the stock. 1492 Capital Management LLC bought a new position in Adaptive Biotechnologies in the 4th quarter worth approximately $1,484,000. UBS Group AG boosted its position in Adaptive Biotechnologies by 101.6% in the 4th quarter. UBS Group AG now owns 511,927 shares of the company's stock valued at $8,314,000 after buying an additional 257,947 shares during the last quarter. Jupiter Asset Management Ltd. boosted its position in Adaptive Biotechnologies by 33.8% in the 4th quarter. Jupiter Asset Management Ltd. now owns 362,811 shares of the company's stock valued at $5,892,000 after buying an additional 91,683 shares during the last quarter. Jennison Associates LLC increased its stake in shares of Adaptive Biotechnologies by 103.9% in the 4th quarter. Jennison Associates LLC now owns 2,674,668 shares of the company's stock valued at $43,437,000 after buying an additional 1,363,181 shares during the period. Finally, Rhenman & Partners Asset Management AB raised its position in shares of Adaptive Biotechnologies by 22.2% during the fourth quarter. Rhenman & Partners Asset Management AB now owns 605,000 shares of the company's stock worth $9,825,000 after acquiring an additional 110,000 shares during the last quarter. Institutional investors and hedge funds own 99.17% of the company's stock.
Adaptive Biotechnologies Company Profile
(
Get Free Report)
Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.
The company's flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
